LENOIR, N.C.--(BUSINESS WIRE)--July 20, 2006--Greer, a leading developer and provider of allergy immunotherapy products, announced the initiation of a Phase IIB double-blind placebo controlled dose response trial for sublingual-oral immunotherapy of its standardized short ragweed extract after receiving clearance of the study protocol from the FDA. The Phase IIB trials will evaluate the safety and efficacy of sublingual-oral immunotherapy in adults with short ragweed pollen allergy. Patient recruitment and screening has begun at four allergy specialty clinics in the United States.
